SCHEMBL21183552

SCHEMBL21183552

COc1ccccc1CNC(=O)C(=O)C(C)N(C=O)c1ccccc1OC

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.51
HTT P42858 2/20 0.51
ALDH1A1 P00352 4/20 0.48
TSHR P16473 1/20 0.48
POLB P06746 2/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPSR1 Q6W5P4 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MAPT P10636 1/20 0.45
BLM P54132 1/20 0.45
HDAC1 Q13547 1/20 0.44
ANPEP P15144 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 1/20 0.44
RCE1 Q9Y256 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974779 0.92 KMT2A (0.46) HPGDHTTALDH1A1TSHRPOLB
SCHEMBL21183551 0.91 MAPT (0.54) HPGDHTTALDH1A1TSHRPOLB
SCHEMBL28876095 0.91 HPGD (0.42) HPGDHTTALDH1A1TSHRPOLB
SCHEMBL19975219 0.89 LMNA (0.47) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL19975096 0.86 HPGD (0.47) HPGDHTTALDH1A1MEN1KMT2A
SCHEMBL19974718 0.86 HPGD (0.39) HPGDHTTALDH1A1POLBMEN1
SCHEMBL19974712 0.86 CARM1 (0.45) ALDH1A1NPC1RAB9AMAPTHSD17B10
SCHEMBL19975281 0.85 ALDH1A1 (0.45) HPGDALDH1A1POLBMEN1KMT2A
SCHEMBL19974685 0.85 POLB (0.51) ALDH1A1POLBRAB9A
SCHEMBL28315333 0.85 CAPN1 (0.39) HPGDALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C HPGD 1205/4885HTT 3380/4885ALDH1A1 2271/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C HPGD 1205/4885HTT 3380/4885ALDH1A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.